References
- Bjorkman DJ. Nonsteroidal anti-inflamatory drug-induced gastrointestinal injury. American Journal of Medicine 1996; 101: 25S–32S
- Conti B, Giunchedi P, Conte U. Cellulose microparticles in drug delivery. STP Pharmaceutical Sciences 1997; 7: 331–342
- Dahl SL, Ward JR. Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new non steroidal anti-inflamatory agent. Pharmatherapy 1982; 2: 80–89
- Hosny EA, El-Mahrouk GM, Gouda MW. Formulation and in vitro and in vivo availability of diclofenac sodium enteric coated beads. Drug Development and Industrial Pharmacy 1998; 24: 661–666
- Information sheets. Eudragit polymethacrylate for pharmaceutical applications. Röhm Pharma, New JerseyUSA 1995
- Katzung BG. Basic and clinical pharmacology, 6th. Prentice-Hall International Inc, New JerseyUSA 1995; 446–448
- Li SP, Kowalski CR, Feld KM, Grim WM. Recent advances in microencapsulation technology and equipment. Drug Development and Industrial Pharmacy 1988; 14: 353–376
- Luzzi LA. Encapsulation techniques for pharmaceuticals :Considerations for the microencapsulation of drugs. Microencapsulation, JR Nixon. Marcel Decker, New York 1976; 193–206
- Ré MI, Biscans B. preparations of microspheres of ketoprofen with acrylic polymers by a quasi-emulsion solvent diffusion method. Powder Technology 1999; 101: 120–133
- Rodriguez M, Vila-Jato JL, Torres D. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. Journal of Controlled Release 1998; 55: 67–77
- Squillante E, Morshed G, Bagchi S, Mehta KA. Microencapsulation of β-galactosidase with eudragit L 100. Journal of Microencapsulation 2003; 20: 153–167
- Stithit S, Chen W, Price JC. Development and characterization of buoyant theophylline microspheres with near zero order release kinetics. Journal of Microencapsulation 1998; 15: 725–737
- Sumano H, De Vizcaya A. Tolerance and clinical evaluation of piroxicam in dogs. Canine Practice 1996; 21: 16–19